NRC Stock Chart & Stats
€1.16
-€0.05(-3.68%)
At close: 4:00 PM EST
€1.16
-€0.05(-3.68%)
Day’s Range― - ―
52-Week Range€0.98 - €3.94
Previous CloseN/A
Volume0.00
Average Volume (3M)33.00
Market Cap
€85.75M
Enterprise Value€156.38M
Total Cash (Recent Filing)€13.21M
Total Debt (Recent Filing)€85.39M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 04, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding69,587,840
10 Day Avg. Volume100
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.07
Price to Sales (P/S)0.61
P/FCF Ratio-4.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.62Price Target Upside126.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€138.16M
Bulls Say, Bears Say
Bulls Say
Revenue Rebound / System MomentumA 166% TTM revenue rebound and year-over-year system shipment growth indicate accelerating adoption of NeuroStar devices. Durable installed-base expansion drives recurring consumables and service revenue, reinforcing predictable revenue streams and supporting scale economics over the coming months.
Sustainable Gross MarginsPersistently high gross margins (guidance 47%–49%, TTM ~48%) suggest structural product and consumable economics. Strong product-level margins provide room to invest in sales and support while protecting profitability as revenue scales, helping the company move toward sustainable positive operating leverage.
Payer Tailwinds / Addressable Market ExpansionPolicy change allowing nurse practitioners to deliver TMS in many states expands covered lives (~34.8M). This materially broadens the addressable market, reduces access barriers, and can sustainably raise utilization and clinic adoption over months as providers integrate TMS into broader outpatient care models.
Bears Say
Continued Cash BurnOngoing negative operating and free cash flow (TTM roughly -$12.8M and -$13.6M) implies sustained funding needs. Persistent cash burn can force financing at unfavorable terms, restrict investment in commercialization and R&D, and raises execution risk until operations generate consistent positive cash flow.
Pressured Balance Sheet / Elevated LeverageLow shareholder equity (~$13.3M) and elevated debt-to-equity (~1.82x) leave limited capital cushioning. Even with reduced debt, the capital structure remains strained, increasing vulnerability to revenue hiccups and potentially limiting strategic flexibility until profitability rebuilds equity.
Persistent GAAP LossesDeep negative margins (TTM net ~-25%, EBIT ~-19%) mean the business is not yet self-sustaining. Continued GAAP losses require sustained margin improvement and demand growth to achieve break-even; until then, management must balance growth investments with tight cost control under funding constraints.
Neuronetics News
NRC FAQ
What was Neuronetics’s price range in the past 12 months?
Neuronetics lowest stock price was €0.98 and its highest was €3.94 in the past 12 months.
What is Neuronetics’s market cap?
Neuronetics’s market cap is €85.75M.
When is Neuronetics’s upcoming earnings report date?
Neuronetics’s upcoming earnings report date is Aug 04, 2026 which is in 31 days.
How were Neuronetics’s earnings last quarter?
Neuronetics released its earnings results on May 05, 2026. The company reported -€0.14 earnings per share for the quarter, beating the consensus estimate of -€0.152 by €0.012.
Is Neuronetics overvalued?
According to Wall Street analysts Neuronetics’s price is currently Undervalued.
Does Neuronetics pay dividends?
Neuronetics does not currently pay dividends.
What is Neuronetics’s EPS estimate?
Neuronetics’s EPS estimate is -0.11.
How many shares outstanding does Neuronetics have?
Neuronetics has 69,587,840 shares outstanding.
What happened to Neuronetics’s price movement after its last earnings report?
Neuronetics reported an EPS of -€0.14 in its last earnings report, beating expectations of -€0.152. Following the earnings report the stock price went up 4.204%.
Which hedge fund is a major shareholder of Neuronetics?
Currently, no hedge funds are holding shares in DE:NRC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuronetics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€2.62 (126.11% Upside)
€2.62 (126.11% Upside)
Blogger Sentiment
Bullish
DE:NRC Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €928.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.77%
12-Months-Change
Fundamentals
Return on Equity
-164.68%
Trailing 12-Months
Asset Growth
-11.65%
Trailing 12-Months
Company Description
Neuronetics
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
NRC Company Deck
NRC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a mixed but constructive view: top-line growth (total revenue +8%, clinic revenue +15%), improved profitability trends (narrower net loss and $2.0M adjusted EBITDA improvement), and meaningful operational initiatives (cost savings, go-to-market pilots, payer/regulatory tailwinds). Offsetting these positives are ongoing challenges including NeuroStar treatment revenue declines, gross margin contraction, a materially reduced cash balance ($19.0M vs $34.1M at year-end), continued GAAP losses and a near-term projected operating cash burn for the year. Management emphasized discipline, cash-flow focus, and pilots to expand reach — signaling a path to stabilization but with execution and liquidity risks to manage in the near term.View all DE:NRC earnings summariesNRC Stock 12 Month Forecast
Average Price Target
€2.62
▲(126.11% Upside)
Technical Analysis
Aclaris Therapeutics
―
MDxHealth
―
Exagen
―
Prenetics Group
―
Atlantic International
―
Options Prices
Currently, No data available
---